The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Causal Relationships between Lipid-Lowering Drug Target and Aortic Disease and Calcific Aortic Valve Stenosis: A Two-Sample Mendelian Randomization
Open accessAbstract
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), cholesteryl ester transfer protein (CETP) and apolipoprotein C3 (APOC3) are pivotal regulators of lipid metabolism, with licensed drugs targeting these genes. The use of lipid-lowering therapy via the inhibition of these genes has demonstrated a reduction in the risk of cardiovascular disease. However, concerns persist regarding their potential long-term impact on aortic diseases and calcific aortic valve disease (CAVS). This study aims to investigate causal relationships between genetic variants resembling these genes and aortic disease, as well as calcific aortic valve disease using Mendelian randomization (MR). Methods: We conducted drug-target Mendelian randomization employing summary-level statistics of low-density lipoprotein cholesterol (LDL-C) to proxy the loss-of-function of PCSK9, HMGCR, CETP and APOC3. Subsequently, we investigated the association between drug-target genetic variants and calcific aortic valve stenosis and aortic diseases, including thoracic aortic aneurysm (TAA), abdominal aortic aneurysm (AAA), and aortic dissection (AD). Results: The genetically constructed variants mimicking lower LDL-C levels were associated with a decreased risk of coronary artery disease, validating their reliability. Notably, HMGCR inhibition exhibited a robust protective effect against TAA (odds ratio (OR): 0.556, 95% CI: 0.372–0.831, p = 0.004), AAA (OR: 0.202, 95% CI: 0.107–0.315, p = 4.84 × 10-15), and AD (OR: 0.217, 95% CI: 0.098–0.480, p = 0.0002). Similarly, PCSK9, CETP and APOC3 inhibition proxies reduced the risk of AAA (OR: 0.595, 95% CI: 0.485–0.730, p = 6.75 × 10-7, OR: 0.127, 95% CI: 0.066–0.243, p = 4.42 × 10-10, and OR: 0.387, 95% CI: 0.182–0.824, p = 0.014, respectively) while showing a neutral impact on TAA and AD. Inhibition of HMGCR, PCSK9, and APOC3 showed promising potential in preventing CAVS with odds ratios of 0.554 (OR: 0.554, 95% CI: 0.433–0.707, p = 2.27 × 10-6), 0.717 (95% CI: 0.635–0.810, p = 9.28 × 10-8), and 0.540 (95% CI: 0.351–0.829, p = 0.005), respectively. However, CETP inhibition did not demonstrate any significant benefits in preventing CAVS (95% CI: 0.704–1.544, p = 0.836). The consistency of these findings across various Mendelian randomization methods, accounting for different assumptions concerning genetic pleiotropy, enhances the causal inference. Conclusions: Our MR analysis reveals that genetic variants resembling statin administration are associated with a reduced risk of AAA, TAA, AD and CAVS. HMGCR, PCSK9 and APOC3 inhibitors but not CETP inhibitors have positive benefits of reduced CAVS. Notably, PCSK9, CETP and APOC3 inhibitors exhibit a protective impact, primarily against AAA, with no discernible benefits extending to TAA or AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies together with ours using different IVs construction strategy have all identified the protective role of PCSK inhibitor on CAVS46–48, which further confirmed the validity of our finding.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449 · cited 1×
“In 2019, a total of 172,000 deaths were attributed to aortic aneurysms [4], encompassing both TAA and AAA, reflecting a concerning trend driven by population growth and aging.”
BackgroundBowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816 · cited 1×
“If the intercept term equals zero precisely, the MR-Egger estimate aligns with the IVW estimate [34].”
MethodBowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922 · cited 1×
“Median weighting, which assesses whether the majority of genetic variants are associated with the outcomes, was performed as part of sensitivity analysis [33].”
BackgroundVerbanck, M., Chen, C.-Y., Neale, B., & Do, R. (2018) · Nature Genetics · doi:10.1038/s41588-018-0099-7 · Cited by 8,591 · cited 1×
“MR-PRESSO, meanwhile, was utilized to automatically detect potential outliers and remove SNPs exhibiting potential pleiotropy [35].”
MethodEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 1×
“Phase 3 clinical trials have demonstrated their beneficial effects in treating high-cardiovascular-risk patients [45].”
BackgroundMendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618 · cited 1×
“The IVW method furnishes a summary estimate of the causal effect of exposure on the outcome by amalgamating estimates from each SNP, with weights determined by the inverse of each instrument’s effect estimate variance [32].”
MethodInterpreting findings from Mendelian randomization using the MR-Egger method.
Burgess, S., & Thompson, S. G. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0255-x · Cited by 4,571
FinnGen provides genetic insights from a well-phenotyped isolated population
Kurki, M. I., Karjalainen, J., Palta, P., Sipilä, T. P., Kristiansson, K., Donner, K. M., Reeve, M. P., Laivuori, H., Aavikko, M., Kaunisto, M. A., et al. (2023) · Nature · doi:10.1038/s41586-022-05473-8 · Cited by 4,233 · cited 1×
“Summary-level data of aortic diseases and CAVS were extracted from the latest R9 release of the FinnGen GWAS results [30].”
MethodWiller (2013) · doi:10.1038/ng.2797 · Cited by 2,983 · cited 1×
“Summary statistics for LDL-C were sourced from the Global Lipids Genetics Consortium (GLGC), which conducted a case-control GWAS meta-analysis encompassing 173,082 individuals from 60 studies [28].”
MethodA comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Isselbacher, E. M., Preventza, O., Hamilton Black, J., Augoustides, J. G., Beck, A. W., Bolen, M. A., Braverman, A. C., Bray, B. E., Brown-Zimmerman, M. M., Chen, E. P., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001106 · Cited by 2,082
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146 · cited 1×
“However, several randomized controlled trials have indicated that lipid-lowering therapy does not impede the progression of CAVS or reduce adverse aortic valve-related events [50– 52].”
BackgroundNicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., et al. (2020) · JAMA · doi:10.1001/jama.2020.22258 · Cited by 1,028
Chan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815 · cited 1×
“However, several randomized controlled trials have indicated that lipid-lowering therapy does not impede the progression of CAVS or reduce adverse aortic valve-related events [50– 52].”
BackgroundVariation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604304 · Cited by 743
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703 · cited 2×
“Several prior studies have utilized drug targets of PCSK9 and HMGCR to explore their effects across diverse health domains, including cardiovascular diseases, diabetes, cancer, and neurocognitive function [25,27,37,38].”
BackgroundSakalihasan, N., Michel, J.-B., Katsargyris, A., Kuivaniemi, H., Defraigne, J.-O., Nchimi, A., Powell, J. T., Yoshimura, K., & Hultgren, R. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0030-7 · Cited by 641
Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes
Bossone, E., & Eagle, K. A. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00472-6 · Cited by 488 · cited 3×
“While aortic diseases exhibit distinct differences in terms of population prevalence, modes of inheritance, and predisposing genes, they also share common risk factors, including a family history of the disease, hypertension, smoking, and atherosclerosis [1,5].”
BackgroundInfluentialGenetics of Thoracic and Abdominal Aortic Diseases: Aneurysms, Dissections, and Ruptures
Pinard, A., Jones, G. T., & Milewicz, D. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.312436 · Cited by 453 · cited 2×
“While aortic diseases exhibit distinct differences in terms of population prevalence, modes of inheritance, and predisposing genes, they also share common risk factors, including a family history of the disease, hypertension, smoking, and atherosclerosis [1,5].”
BackgroundNienaber, C. A., Clough, R. E., Sakalihasan, N., Suzuki, T., Gibbs, R., Mussa, F., Jenkins, M. P., Thompson, M. M., Evangelista, A., Yeh, J. S. M., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.53 · Cited by 400
Luan, Z., Chase, A. J., & Newby, A. C. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000068646.76823.ae · Cited by 341 · cited 1×
“Both in vitro and in vivo evidence suggest a correlation between statin therapy and reduced expression of metalloproteinases and proteolytic enzymes, whose upregulation promotes inflammation, leading to smooth muscle apoptosis [42].”
BackgroundAortic Valve Stenosis: From Basic Mechanisms to Novel Therapeutic Targets
Goody, P. R., Hosen, M. R., Christmann, D., Niepmann, S. T., Zietzer, A., Adam, M., Bönner, F., Zimmer, S., Nickenig, G., & Jansen, F. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313067 · Cited by 331
Sampson, U. K. A., Norman, P. E., Fowkes, F. G. R., Aboyans, V., Song, Y., Harrell Jr., F. E., Forouzanfar, M. H., Naghavi, M., Denenberg, J. O., McDermott, M. M., et al. (2014) · Global Heart · doi:10.1016/j.gheart.2013.12.010 · Cited by 298 · cited 1×
“Globally, the death rates attributed to aortic diseases have risen from 2.49 per 100,000 in 1990 to 2.78 per 100,000 in 2010 [3].”
BackgroundInfluentialThe Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264
Association Between Cardiovascular Risk Factors and Aortic Stenosis
Yan, A. T., Koh, M., Chan, K. K., Guo, H., Alter, D. A., Austin, P. C., Tu, J. V., Wijeysundera, H. C., & Ko, D. T. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.025 · Cited by 247 · cited 1×
“The CANHEART cohort study demonstrated an increased risk of severe aortic valve stenosis development in older adults with dyslipidemia (adjusted OR: 1.17, 95% CI: 1.14–1.21, p 0.001) [49].”
BackgroundInfluentialSong, P., He, Y., Adeloye, D., Zhu, Y., Ye, X., Yi, Q., Rahimi, K., Rudan, I., & on behalf of the Global Health Epidemiology Research Group (GHERG) (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005716 · Cited by 179 · cited 1×
“Population-based screening studies have estimated a varying prevalence of AAA, ranging from 1.9% to 18.5% in men and 0.1% to 1.2% in women [2].”
BackgroundInfluentialBenn, M., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A. (2017) · BMJ · doi:10.1136/bmj.j1648 · Cited by 178
Nicholls, S. J., Ditmarsch, M., Kastelein, J. J., Rigby, S. P., Kling, D., Curcio, D. L., Alp, N. J., & Davidson, M. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01936-7 · Cited by 174 · cited 1×
“Recent phase 3 and phase 2 clinical trials investigating APOC and CETP inhibitors have shown encouraging results, with reductions in plasma LDL-C levels and fewer adverse cardiovascular events [47,48].”
BackgroundPlasma lipids and risk of aortic valve stenosis: a Mendelian randomization study
Nazarzadeh, M., Pinho-Gomes, A.-C., Bidel, Z., Dehghan, A., Canoy, D., Hassaine, A., Ayala Solares, J. R., Salimi-Khorshidi, G., Smith, G. D., Otto, C. M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa070 · Cited by 163 · cited 3×
“However, randomized controlled trials have failed to demonstrate the benefits of statins in preventing the progression of aortic stenosis [24].”
InfluentialSalata, K., Syed, M. H., Hussain, M. A., de Mestral, C., Greco, E., Mamdani, M., Tu, J. V., Forbes, T. L., Bhatt, D. L., Verma, S., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008657 · Cited by 156 · cited 2×
“Previous studies have demonstrated that statins not only reduce perioperative morbidity and mortality rates during vascular surgery, including procedures for aortic aneurysms, but also decrease long-term adverse events and aneurysm growth in both AAA and TAA [8,12, 15].”
BackgroundAddressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150 · cited 1×
“…therapy for many years, newer medications such as proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) inhibitors, cholesteryl ester transfer protein ( CETP ) inhibitors and apolipoprotein C3 ( APOC3 ) inhibitors have emerged as novel targets for cholesterol-lowering drug development [18–21].”
BackgroundCholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
Schmidt, A. F., Hunt, N. B., Gordillo‐Marañón, M., Charoen, P., Drenos, F., Casas, J. P., Mika Kivimaki, B., Lawlor, D. A., Giambartolomei, C., Papacosta, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25703-3 · Cited by 148
Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis
Harrison, S. C., Holmes, M. V., Burgess, S., Asselbergs, F. W., Jones, G. T., Baas, A. F., Hof, F. N. G. V. ’., de Bakker, P. I. W., Blankensteijn, J. D., Powell, J. T., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4293 · Cited by 144 · cited 1×
“[54] supported the hypothesis that lipids play a significant role in the development of AAA and suggested that LDL-C lowering drugs might serve as a potential treatment.”
BackgroundRole of Resident Stem Cells in Vessel Formation and Arteriosclerosis
Zhang, L., Bhaloo, S. I., Chen, T., Zhou, B., & Xu, Q. (2018) · Circulation Research · doi:10.1161/circresaha.118.313058 · Cited by 138 · cited 1×
“At the cellular level, the distinct origins of smooth muscle cells in the thoracic aorta (neural crest and somitic mesoderm) compared to those in the abdominal aorta (splanchnic meso-5 derm) might contribute to different pathogenic mechanisms for AAA when contrasted with TAA and AD [40].”
BackgroundRoychowdhury, T., Klarin, D. M., Levin, M. G., Spin, J. M., Rhee, Y. H., Deng, A. C., Headley, C. A., Tsao, N. L., Gellatly, C., Zuber, V., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01510-y · Cited by 128 · cited 2×
“Further drug-target analyses indicated that higher genetically predicted circulating PCSK9 and lipoprotein(a) were associated with an increased AAA risk, and a pre-clinical mouse model validated the important role of PCSK9 in AAA development [46].”
BackgroundMethodMendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function
Rosoff, D. B., Bell, A. S., Jung, J., Wagner, J., Mavromatis, L. A., & Lohoff, F. W. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.05.041 · Cited by 126 · cited 1×
“In accordance with a previously reported approach [31], we identified single-nucleotide polymorphisms (SNPs) associated with lower LDL-C from the GLGC GWAS results at the genome-wide significance threshold of p 5.0 × 10 − 8 .”
ResultInfluentialYarmolinsky, J., Bull, C. J., Vincent, E. E., Robinson, J., Walther, A., Smith, G. D., Lewis, S. J., Relton, C. L., & Martin, R. M. (2020) · JAMA · doi:10.1001/jama.2020.0150 · Cited by 124 · cited 1×
“Several prior studies have utilized drug targets of PCSK9 and HMGCR to explore their effects across diverse health domains, including cardiovascular diseases, diabetes, cancer, and neurocognitive function [25,27,37,38].”
BackgroundA further meta-analysis of population-based screening for abdominal aortic aneurysm
Takagi, H., Goto, S.-N., Matsui, M., Manabe, H., & Umemoto, T. (2010) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2010.02.283 · Cited by 108 · cited 1×
“Meta-analyses of previous observational studies have suggested a protective effect of high-density lipoprotein cholesterol (HDL-C) on AAA, while the association with low-density lipoprotein cholesterol (LDL-C) is less clear [10,11].”
BackgroundEffect of Statin Drugs on Thoracic Aortic Aneurysms
Stein, L. H., Berger, J., Tranquilli, M., & Elefteraides, J. A. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.05.081 · Cited by 96
Cai, J., Wei, Z., Chen, M., He, L., Wang, H., Li, M., & Peng, Y. (2022) · European Psychiatry · doi:10.1192/j.eurpsy.2022.18 · Cited by 96
Ginsberg, H. N., & Goldberg, I. J. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317966 · Cited by 87
Nienaber, C. A., Clough, R. E., Sakalihasan, N., Suzuki, T., Gibbs, R. G. J., Mussa, F. F., Jenkins, M. P., THOMPSON, M. M., Evangelista, A., Yeh, J. S. M., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.71 · Cited by 74
Interpreting the Clinical Implications of Drug-Target Mendelian Randomization Studies
Ference, B. A. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.007 · Cited by 69 · cited 1×
“However, their analysis did not include TAA and AD for further examination, and only 1-2 SNPs were used to proxy the drug target, which, as reported by Ference [55], may not provide quantitatively reliable estimates when relying solely on rare variants.”
MethodCalcific Aortic Valve Stenosis and Atherosclerotic Calcification
Sá, M. P., Cavalcanti, L. R. P., Perazzo, Á., Gomes, R. A. F., Clavel, M.-A. A., Pîbarot, P., Biondi‐Zoccai, G., Zhigalov, K., Weymann, A., Ruhparwar, A., et al. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0821-7 · Cited by 51 · cited 1×
“Mechanically, lipid deposition accompanied by injury and inflammation initiates the process followed by osteogenic differentiation and calcification [22,23].”
BackgroundEffects of statin therapy on ascending aorta aneurysms growth: A propensity-matched analysis
Angeloni, E., Vitaterna, A., Pirelli, M., & Refice, S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.001 · Cited by 45 · cited 3×
“Previous studies have demonstrated that statins not only reduce perioperative morbidity and mortality rates during vascular surgery, including procedures for aortic aneurysms, but also decrease long-term adverse events and aneurysm growth in both AAA and TAA [8,12, 15].”
BackgroundResultCurrent Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm
Yoshimura, K., Morikage, N., Fujimoto, S. N., Furutani, A., Shirasawa, B., & Hamano, K. (2017) · Current Drug Targets · doi:10.2174/1389450119666171227223331 · Cited by 45
Pitavastatin, an HMG-CoA Reductase Inhibitor, Ameliorates Endothelial Function in Chronic Smokers
Yoshida, O., Kondo, T., Kureishi-Bando, Y., Sugiura, T., Maeda, K., Okumura, K., & Murohara, T. (2009) · Circulation Journal · doi:10.1253/circj.cj-09-0345 · Cited by 42 · cited 1×
“…statins effectively ameliorate endothelial dysfunction through pleiotropic actions, including increasing the expression of endothelial nitric oxide synthase (eNOS), promoting nitric oxide production, inhibiting Rho prenylation, and exerting antioxidant and anti-inflammatory effects [43,44].”
BackgroundPCSK9-targeted therapies: present and future approaches
Rifai, M. A., & Ballantyne, C. M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00634-0 · Cited by 37 · cited 1×
“…therapy for many years, newer medications such as proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) inhibitors, cholesteryl ester transfer protein ( CETP ) inhibitors and apolipoprotein C3 ( APOC3 ) inhibitors have emerged as novel targets for cholesterol-lowering drug development [18–21].”
BackgroundEffect of statins on abdominal aortic aneurysm
Hosseini, A., Sahranavard, T., Reiner, Ž., Jamialahmadi, T., Dhaheri, Y. A., Eid, A. H., & Sahebkar, A. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106284 · Cited by 30 · cited 1×
“Despite the uncertainty surrounding the association between lipid levels and AAA in observational research, statin use has consistently demonstrated a robust protective effect on AAA with reduced adverse outcomes [12–14].”
BackgroundIn vitro antioxidant activity of pravastatin provides vascular protection
Kassan, M., Montero, M. J., & Sevilla, M. A. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.037 · Cited by 26
A Meta-Analysis of Association Between Serum Lipoproteins and Abdominal Aortic Aneurysm
Takagi, H., Manabe, H., & Umemoto, T. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.021 · Cited by 23
Chen, Y., Huang, M., Xuan, Y., Li, K., Xu, X. P., Wang, L., Sun, Y., Xiao, L., Xu, P., Kong, W., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111171 · Cited by 20 · cited 1×
“[56] and Li et al .”
Pena, R. C. F., Bowman, M. A. H., Ahmad, M., Pham, J., Kline-Rogers, E. M., Case, M., Lee, J., Eagle, K. A., Cotter, N. E., David, C. C., et al. (2022) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2022.02.007 · Cited by 20 · cited 1×
“In contrast, the beneficial impact of statins on TAA remains uncertain [15–17], and limited data have examined statin use specifically in aortic dissection.”
BackgroundFor the STANP trial investigators, Masaki, N., Kumagai, K., Sasaki, K., Matsuo, S., Motoyoshi, N., Adachi, O., Akiyama, M., Kawamoto, S., Tabayashi, K., et al. (2018) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-018-0916-z · Cited by 18 · cited 1×
“Statins are also frequently prescribed to AD patients, although the supporting evidence is not robust [7,9].”
BackgroundLi, R., Zhang, C., Du, X., & Chen, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051991 · Cited by 11 · cited 1×
“[57] also demonstrated a causal relationship between plasma lipids and the risk of aortic aneurysms, highlighting the potential effectiveness of lipid drug targets in preventing and managing aortic aneurysms.”
BackgroundLipid levels linked to symptomatic aortic valve stenosis: evidence from Mendelian randomization?
Nienaber, C. A., & Yuan, X. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa225 · Cited by 3 · cited 1×
“While the use of Mendelian randomization is in-triguing, its fallout may help elucidate isolated elements of disease mechanism, but certainly not the entire complexity of progressive valve disease [53].”
BackgroundStatins for Patients Undergoing Thoracic Aortic Aneurysm Repair Surgery: What to Do?
Klein, K. M., & Jovin, I. S. (2021) · Aorta · doi:10.1055/s-0041-1736589 · Cited by 3
Cited by
Antiviral drug discovery and development: challenges and future directions
Du, S., Hu, X., Li, P., Xu, S., Kim, M., Liu, X., & Zhan, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02539-7 · Cited by 51
Wu, C., Pu, Q., Zou, Y., Jin, J., Lei, Y., Hu, Y., Chen, Z., & Yu, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-15525-4 · Cited by 3
The two faces of cholesteryl ester transfer protein inhibitors
Pirillo, A., & Catapano, A. L. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001017 · Cited by 2
Genetically predicted high-density lipoprotein traits and pan-disease risk: a systematic review
Wu, J., Su, B., Fan, Z., & Zhan, H. (2026) · Epidemiologic Reviews · doi:10.1093/epirev/mxag001 · Cited by 1
Hou, J., Lin, L., Huang, J., Chai, Q., Wang, S., Liu, X., & Liu, Q. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177838 · Cited by 2
Metadata
- Authors
- Yang, L., Xu, M., Gao, X., Liu, J., Zhang, D., Zhang, Z., Ye, Z., Wen, J., & Liu, P.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Corresponding author
- Wen, Jianyan
- Liu, Peng
- Venue
- Reviews in Cardiovascular Medicine
- Publisher
- IMR Press
- Published
- 2024-08-19
- Volume
- 25
- Issue
- 8
- Pages
- 292-292
- ISSN
- 1530-6550 (ISSN-L)
- 2153-8174
- PMC
- PMC11367000
- OpenAlex
- W4402012467
- Cited by
- 6
- References
- 59
- Citations by year
- 2026: 3 · 2025: 3
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Reviews in Cardiovascular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82270443, 82170066, 81670275, 81670443)
- National High Level Hospital Clinical Research Funding (2022-NHLHCRF-ZSYX-01)
- International S&T cooperation program (2013DFA31900)
- Major New Drug Creation Special Project, Ministry of Science and Technology of the People’s Republic of China (2020ZX09201-012)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- calcific aortic stenosis, aortic disease, thoracic aortic aneurysm, abdominal aortic aneurysm, aortic dissection, PCSK9, HMGCR, cholesteryl ester transfer protein, apolipoprotein C-III, lipid-lowering drugs, LDL cholesterol, coronary artery disease, causal relationship, statins, ezetimibe
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.